Home › Endometrial Cancer › Nevada › Reno
Endometrial Cancer clinical trials in Reno, NV
4 studies for Endometrial Cancer are looking for participants at sites in and around Reno (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- Renown Regional Medical Center, Reno
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
RecruitingPhase 3
- The Center of Hope Reno, Reno
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
RecruitingPhase 3
- The Center of Hope ( Site 5018), Reno
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
RecruitingPhase 3
- The Center of Hope, Reno
Endometrial Cancer trials in other cities
- Houston, TX69 studies
- New York City, NY54 studies
- Boston, MA51 studies
- Arlington, VA41 studies
- Nashville, TN38 studies
- Los Angeles, CA35 studies
- St. Louis, MO29 studies
- Philadelphia, PA29 studies
- Oklahoma City, OK28 studies
- San Antonio, TX27 studies
- Queens, NY26 studies
- Dallas, TX25 studies
Other studies in Reno
- Non-Small Cell Lung Cancer16 studies
- Breast Cancer15 studies
- Lung Cancer9 studies
- Geographic Atrophy8 studies
- Macular Degeneration7 studies
- Cancer (all types)7 studies
- Ovarian Cancer6 studies
- Pancreatic Cancer5 studies
- Metastatic Cancer5 studies
- Colon Cancer5 studies
- Colorectal Cancer5 studies
- Rectal Cancer4 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.